India's economic engine is revving up, but navigating the global headwinds requires sharp strategy. The rupee's recent volatility against the dollar underscores the complexities facing Indian businesses, impacting everything from import-export trade to domestic inflation. This week alone, we've seen significant shifts in the IT sector, with major players announcing restructuring and a renewed focus on AI-driven solutions. Meanwhile, the burgeoning startup ecosystem continues to attract substantial funding, despite a cautious global investor sentiment. The government's recent policy announcements on infrastructure development and digitalization are poised to further shape the business landscape, creating both opportunities and challenges for entrepreneurs and established corporations alike. Understanding these market dynamics is crucial for success in today's rapidly evolving Indian economy. Stay informed with Abtak.com for the latest insights and analysis on key sectors including finance, manufacturing, and technology – empowering your business decisions in a dynamic market. Explore the complete business news section now to stay ahead of the curve.
New Delhi, Jun 27 (PTI) Biocon Ltd on Friday said its arm Biocon Biologics has been granted a notice of compliance by Health Canada for its biosimilar Yesafili injection used to treat various ailments of the eye. "Health Canada has granted a Notice of Compliance (NOC) for Yesafili(aflibercept), a biosimilar to Eylea injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL on June 26, 2025," a regulatory filing by Biocon said. This approval paves the way for the launch of Yesafili in Canada, scheduled for July 4, 2025, it said, adding Yesafili is the first biosimilar to Eylea to be approved by Health Canada. Yesafili is indicated for treatment of various eye ailments, including neovascular (wet) age-related macular degeneration , visual impairment due to macular edema secondary to central retinal vein occlusion, visual impairment due to macular edema secondary to branch retinal vein occlusion, diabetic macular edema (DME) and myopic choroidal neovascularisation, the company added. "...Canada will be the first country where we will launch Yesafili, making it our 10th biosimilar to be commercialised worldwide. This milestone reflects our science-driven innovation, global commercialization strength, and continued commitment to expanding access to high-quality, affordable biologics for patients across the globe," Biocon Biologics CEO & MD Shreehas Tambe said. The approval by Health Canada is based on a comprehensive package of analytical, nonclinical, and clinical data, confirming that Yesafili is highly similar with no clinically meaningful differences to Eylea in terms of quality, safety, and efficacy, the company said. PTI RKL ANU ANU
Bengaluru (Karnataka) [India], July 3 (ANI): Kiran Mazumdar Shaw, the Executive Chairperson of Biocon Limited, refuted the allegation of the Karnataka Chief Minister Siddaramaiah, in which he attributed more than twenty deaths due to heart attacks in the past one month in district of Hassan to COVID vaccines. She said that it was factually incorrect to suggest that COVID vaccines were hastily approved. Also Read | Heart Attacks Being Linked to COVID-19 Vaccines After 4 Years of Being Vaccinated Does Not Stack Up, Says Biocon Chief Kiran Mazumdar-Shaw. In a post on X, Kiran Mazumdar Shaw sai ...Read More >
VMPL New Delhi [India], July 18: In recent times, many of us have encountered the term 'Progressive Myopia'. But what exactly is it? Progressive Myopia is a form of near-sightedness where the correction needed to clear vision increases by more than -0.5 dioptre within a year. This condition predominantly affects children and teenagers. The earlier Myopia develops, the faster it progresses. Consequently, children who develop Myopia early in life are more susceptible to progressive myopia and eventually high myopia. Dr Padma Priya G K, MBBS, DO, DNB, FPOS, FAICO Consultant Paediatric Ophthal ...Read More >
Bengaluru: Biocon Limited has achieved a regulatory milestone in the United States, reinforcing its presence in the global diabetes treatment market. Biocon Pharma Limited, a subsidiary of Biocon Limited, has received approval from the U.S. Food and Drug Administration for Dapagliflozin Tablets in 5 mg and 10 mg strengths. The approval enables the company to market the drug for adults with type 2 diabetes mellitus, expanding its footprint in one of the world's largest pharmaceutical markets. The approved drug is indicated as an adjunct to diet and exercise to improve glycemic control in adul ...Read More >
New Delhi, Oct 20 (SocialNews.XYZ) A wireless retinal implant showed potential to restore central vision in patients with advanced age-related macular degeneration (AMD), according to clinical trial results published on Monday. Advanced atrophic AMD, also known as geographic atrophy (GA), is the leading cause of irreversible blindness in older adults, affecting more than 5 million people worldwide. The study, led by researchers from the University College London, University of Pittsburgh, and Stanford Medicine revealed that 27 out of 32 participants had regained the ability to read a year af ...Read More >
Hyderabad: The Chintan Shivir on the Pharmaceutical Sector, organized by the Pharmaceutical Export Promotion Council of India (PHARMEXCIL), with the support of the Ministry of Commerce & Industry, Government of India, concluded successfully today in Hyderabad. This event marked the continuation of the series of discussions, following successful editions in Chandigarh and Ahmedabad, and served as a platform for strengthening India's pharmaceutical export agenda. The inaugural session, chaired by Shri Rajesh Agrawal, IAS, Commerce Secretary, Department of Commerce and Industry, Ministry of Comm ...Read More >
Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global markets. Keytruda (generic name is pembrolizumab), manufactured and marketed by Merck & Co, is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of cancer. Under the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and ...Read More >
New Delhi [India], July 18: Myopia, or near-sightedness, is a condition where nearby objects appear clear, but distant objects look blurry. It is the most common refractive error, typically affecting the younger population worldwide. With its rising prevalence, it is estimated that by 2050, half of the global population will be Myopic. Quote: Myopia, or near-sightedness, is rapidly increasing among children, Today children are spending less time outdoors and more time on screens, and these lifestyle factors, along with genetics, are contributing significantly to the rise in myopia. Once myopi ...Read More >
Raichur (Karnataka) [India], August 14: In a landmark moment for global hepatology and Indian pharmaceutical innovation, Shilpa Medicare Limited (BSE: 530661) (NSE: SHILPAMED) has secured the world first regulatory approval from India Central Drugs Standard Control Organization (CDSCO) for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, the first-ever approved therapy targeting NAFLD. * Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty Liver Disease (NAFLD) * NAFLD affects 1 in 4 people ...Read More >
New Delhi: Commerce secretary Rajesh Agrawal Saturday asked the pharmaceutical industry to reduce its dependence on critical imported raw materials by meeting atleast 80-90% of domestic pharmaceutical requirements through indigenous production. Addressing an event in Hyderabad, he said while India exports to around 200 countries, there remains significant scope for expansion and resilience-building through a stronger market presence. Emphasising the need to navigate an increasingly uncertain and geopolitically volatile global environment, he said: "The importance of ensuring greater self-rel ...Read More >
Hyderabad: CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, on Monday said it has reported positive top-line Phase 3 results for BP11, its investigational biosimilar to Xolair, or omalizumab.CuraTeQ said the study met all primary endpoints in patients with chronic spontaneous urticaria receiving the 300 mg dose, demonstrating high comparability with the reference product. The company said it plans to use the results to support regulatory submissions for chronic spontaneous urtica ...Read More >
Agartala (Tripura) [India], June 5 (ANI): Tripura Chief Minister Manik Saha said that the state government is prioritising quality education for students, and quality teachers are being recruited through the Teacher Eligibility Test (TET). Saha also informed that more recruitments will be made in the future. Also Read | Centre Notifies Waqf Management Rules 2025; Portal, Database, Audit of Waqf Properties. "Textbook education can never be the standard of life. One can become morally strong through education. Along with education, children should also be engaged in social work," he said. CM ...Read More >
For the month, FII sold equities worth Rs 30,141.68 crore, while DII bought equities worth Rs 55,736.09 crore. The broader indices broke a three-week gaining streak and underperformed the main indices as markets remained under pressure throughout the week on worries over fresh tariffs on pharma, higher visa fees by the US, persistent trade concerns, and continued FII selling. For the week, Nifty50 plunged 672.35 points or 2.65 percent to finish at 24,654.70, while the BSE Sensex index declined ...Read More >
New Delhi [India], April 3 (ANI): The recent decision by US President Donald Trump to impose a 100 per cent tariff on patented pharmaceutical imports to US is unlikely to cause immediate disruption to Indian drugmakers, as the move largely targets branded medicines while exempting generics and biosimilars, said Siddharth Mittal, Managing Director and CEO (Designate) Syngene International Limited. Also Read | US Pilot Rescued After Fighter Jet Shot Down in Iran; Helicopter Also Hit During Search. In an exclusive interaction with ANI, Mittal said the tariff action is aimed at boosting domestic ...Read More >
NEW DELHI, Apr 4 : "International Diabetes Federation" (IDF) President-elect, Dr Niti Pall, currently on India visit, called on Union Minister Dr Jitendra Singh, who is also a noted Professor of Medicine & Diabetes, and discussed, among other things, indigenous biosimilar Insulin production as well as Diabetes related indigenous biomanufacturing prospects. The meeting underscored the importance of strengthening India's capabilities in insulin manufacturing, particularly biosimilar insulins and Continuous Glucose Monitoring (CGM) instruments. The discussion brought into focus growing global c ...Read More >
Biocon Biologics, in collaboration with Diabetes Africa and St Paul’s Hospital in Ethiopia, has launched the Embedding Specialist Nurses in Diabetes Care project. The initiative focuses on training nurses to become diabetes specialists to address the country’s growing diabetes crisis. With Ethiopia ranking among the top countries in sub-Saharan Africa for diabetes prevalence, this project aims to integrate diabetes care into primary healthcare, enhancing accessibility and care quality. By upskilling nurses and establishing a structured pathway for them, the program seeks to improve diabetes ma ...Read More >
New Delhi [India], April 3 (ANI): The recent decision by US President Donald Trump to impose a 100 per cent tariff on patented pharmaceutical imports to US is unlikely to cause immediate disruption to Indian drugmakers, as the move largely targets branded medicines while exempting generics and biosimilars, said Siddharth Mittal, CEO and Managing Director of Biocon Limited. Also Read | Mysuru Cloth Bag Scam: Karnataka High Court Orders Probe Against IAS Officer Rohini Sindhuri Over INR 5.8 Crore Irregularities. In an exclusive interaction with ANI, Mittal said the tariff action is aimed at bo ...Read More >
Nivea India Pvt. was named the 'Most Trusted Skincare Brand' in TRA's Brand Trust Report 2025. The company has held this position for the fifth consecutive year. "A brand's performance in TRA's Most Trusted Brands is a direct reflection of consumer sentiment, representing their instinctive response to unaided brand trust attributes. NIVEA India Pvt Ltd. being ranked as the Most Trusted Skincare Brand for the fifth consecutive year is a rare and remarkable accomplishment. It signifies the brand's enduring engagement and consistent delivery on consumer expectations. Trust holds paramount import ...Read More >
Bengaluru, July 4 (SocialNews.XYZ) Karnataka Chief Minister Siddaramaiah, responding to objections raised by Biocon chief Kiran Mazumdar Shaw over his statement on Covid vaccines causing heart attacks in the state, on Friday, remarked that seeking clarity does not amount to spreading misinformation. Taking to social media site X, Siddaramaiah, defending his statement on linking sudden heart attack deaths in Hassan to a "hasty" Covid vaccine rollout, said: "As Chief Minister, I have a duty to respond to the genuine concerns of people who have lost loved ones unexpectedly. When parents lose the ...Read More >
Mumbai: Benchmark stock indices Sensex and Nifty tumbled nearly one per cent on Friday, marking their sixth consecutive day of decline, following heavy selling in pharma and IT shares as US President Donald Trump announced 100 per cent duties on branded drugs from next month. The 30-share BSE Sensex tanked 733.22 points or 0.90 per cent to settle at a three-week low of 80,426.46. During the day, it dropped 827.27 points or one per cent to 80,332.41 points. The 50-share NSE Nifty tumbled 236.15 points or 0.95 per cent to an over three-week low of 24,654.70 points. The index has been on a decli ...Read More >
Raichur (Karnataka) [India], August 14: In a landmark moment for global hepatology and Indian pharmaceutical innovation, Shilpa Medicare Limited (BSE: 530661) (NSE: SHILPAMED) has secured the world's first regulatory approval from India's Central Drugs Standard Control Organization (CDSCO) for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, the first-ever approved therapy targeting NAFLD. Also Read | 'Coolie' X Review: Rajinikanth's 'One-Man Show' With Nagarjuna's Stylish Act and Anirudh Ravichander's BGM Redeems Lokesh Kanagaraj's Massy Thriller, Say Netizens. * Shilpa Medicare emerges a ...Read More >
Thiruvananthapuram: Union Minister Suresh Gopi stirred controversy on Tuesday by claiming that those elected by "corpses" are now serving the state. Speaking at a neighbourhood meet called "Kalungu" in Idukki district, he alleged that cadavers from 25 years ago had cast votes in Kerala elections. Media reports have previously highlighted incidents of deceased voters being listed as active in Kerala's voter list, he said, while indirectly referring to the accusations of "scientific rigging " against the Left parties. The minister was responding to allegations of voter fraud in Thrissur consti ...Read More >
Jayshree Ullal (left), Kiran Mazumdar-Shaw (centre), Falguni Nayar (right) India's businesswomen and entrepreneurs recently made history at the release of the M3M Hurun Rich List 2025 on Wednesday. As per the annual report published by the Hurun Research Institute, which tracks the wealth and assets of India's most affluent groups and families, India's businesswomen made history this week by featuring in the top spot of the Hurun India rich list for the very first time. Roshni Nadar Malhotra (44) & family debut in the Top 3 with a wealth of Rs 2.84 lakh crore, becoming India's richest woman ...Read More >
New Delhi, Dec 15 (PTI) Biocon Ltd on Monday said it has launched its diabetes and chronic weight management injection, Liraglutide, in the Netherlands through its distribution partner, Pharmamedic BV. The drug-device combination will be marketed in the Netherlands under the brand names Diavorin for diabetes and Vobexoryn for chronic weight management, Biocon said in a statement. Liraglutide is a synthetic analog of GLP-1 peptide (glucagon-like peptide-1) that helps lower blood sugar levels and promote weight loss. It is administered as a once-daily injection, the company said. The launch f ...Read More >
New Delhi, Jul 3 (PTI) Biocon Ltd on Thursday said its arm Biocon Biologics Ltd has been granted marketing authorisation by the European Commission for Vevzuo and Evfraxy biosimilars of Denosumab used in the treatment of different bone diseases. The marketing authorisation for the European Union (EU) follows a positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025, Biocon Ltd said in a regulatory filing. Vevzuo is authorised for the prevention of bone complications in adults with advanced cancer involving bone and th ...Read More >
Lucknow: Three day Mango Festival 2025 kicked off at Awadh Shilp Gram in Lucknow, featuring more than 800 mango varieties from across India. The event celebrates mango diversity, horticultural innovation, and the growing role of Uttar Pradesh in India's fruit export ecosystem. Organized with participation from farmers, exporters, scientists, and food processing units, the festival offers a platform to promote mango-based trade and technology. Mangoes like Dussehri from Lucknow, Langda from Varanasi, Amrapali from Basti, Gaurjeet from Gorakhpur, and Ratol from western UP were among the most ad ...Read More >
New Delhi, April 4 (SocialNews.XYZ) Union Minister Dr Jitendra Singh met with International Diabetes Federation President-elect Dr Niti Pall, and the latter highlighted that Asian and African countries "are increasingly looking to India for affordable diabetes care solutions," due to leadership in supplying cost-effective vaccines, an official statement said on Saturday. Dr Singh and Dr Pall discussed indigenous biosimilar insulin production and diabetes related indigenous biomanufacturing prospects, the Ministry of Earth Sciences said in a statement. She pointed out that high insulin prices ...Read More >
Biologic therapies are transforming severe asthma treatment by offering the potential for remission, shifting care from symptom control to targeted, personalized approaches. Treatments like dupilumab and tezepelumab have shown efficacy across diverse patient profiles, including complex asthma cases. However, significant barriers remain, particularly cost and access, limiting their availability, especially in underserved communities. Experts stress the need for equitable healthcare solutions to ensure these transformative treatments reach all patients in need. As biologics continue to revolutio ...Read More >
Biopharmaceutical company Boehringer Ingelheim has launched a next generation poultry vaccine for Marek's disease in the country. The product represents a breakthrough in vaccine engineering and recommended for in-ovo vaccination of 18 to 19-day-old embryonated chicken eggs and one-day old chickens to protect against the virulent Marek's disease, the company said in a release on Tuesday (November 26, 2024). The vaccine offers enhanced protection through an innovative controlled attenuation process, delivering right balance between safety and efficacy. Marek's disease remains a significant ch ...Read More >
New Delhi, Aug 12 (PTI) Drug firm Lupin on Tuesday said it has partnered with Switzerland-based Sandoz Group AG to commercialise its biosimilar ranibizumab across multiple regions. Under the terms of the agreement, Sandoz will oversee commercialisation of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia, the Mumbai-based drug maker said in a statement. Lupin will be responsible for manufacturing the product and for regulatory submissions, it added. As per the deal, Sandoz will hold exclusive marketing rights in most ...Read More >
Wipro founder chairman Azim Premji has declined Chief Minister Siddaramaiah's request to allow limited vehicular movement through the company's campus in Bengaluru, saying that it is an exclusive private property owned by a listed company, not meant for public thoroughfare. He also said that allowing public vehicular movement through Wipro's Sarjapur campus will cause "significant legal, governance, and statutory challenges". Chief Minister Siddaramaiah had on September 19 written to Premji to ...Read More >